Adjuvant Nivolumab in Resected Lung Cancers (ANVIL) ~ A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers (ECOG-ACRIN EA5142)

Study Details

This phase III ALCHEMIST trial studies how well nivolumab after surgery and chemotherapy work in treating patients with stage IB-IIIA non-small cell lung cancer. Monoclonal antibodies, such as nivolumab, may stimulate the immune system in different ways and kill tumor cells remaining after surgery and standard of care chemotherapy.

Learn More

ClinicalTrials.gov NCT number
NCT02595944

Principal Investigators

  • Salvatore Del Prete, MD
Sponsor(s)
National Cancer Institute
Contact
Ed Hatton, RN at 203-358-8879
or officeofresearch@stamhealth.org

Location

  • Bennett Cancer Center
    One Hospital Plaza
    Stamford, CT 06902
    Main: 203-276-2695